title: Sandostatin and the Belfast experience.
abstract: Twenty-four patients with 26 apudomas have been treated with Sandostatin (octreotide) in Belfast. The 2 patients with vipoma showed an excellent response clinically and biochemically. Of 15 patients with carcinoids, Sandostatin improved the diarrhoea in 70%, flush in 58%, and wheeze in 100% of patients. Patients with insulinoma and the Zollinger-Ellison syndrome were unresponsive to Sandostatin. In general, the response to Sandostatin appeared to decline as the tumour size increased and tumour markers rose. Side effects have not been a problem.
authors.affiliation: Institute of Clinical Science, Queen's University, Belfast, UK.
authors.forename: K D
authors.initials: KD
authors.lastname: Buchanan
authors.forename: J S
authors.initials: JS
authors.lastname: Collins
authors.forename: A
authors.initials: A
authors.lastname: Varghese
authors.forename: C F
authors.initials: CF
authors.lastname: Johnston
authors.forename: C
authors.initials: C
authors.lastname: Shaw
mesh_terms: D001079:Apudoma / Q000188:drug therapy*; D002276:Carcinoid Tumor / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D005260:Female; D005483:Flushing / Q000188:drug therapy; D015408:Gastrinoma / Q000188:drug therapy; D006801:Humans; D007340:Insulinoma / Q000188:drug therapy; D009660:Northern Ireland; D015282:Octreotide / Q000627:therapeutic use*; D012135:Respiratory Sounds; D003969:Vipoma / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
chemical_list: D015282:Octreotide